Novel therapeutic RNA interference technology targeted to the PDX-1 oncogene in PDX-1 expressing neuroendocrine tumors

Details for Australian Patent Application No. 2010313441 (hide)

Owner Gradalis, Inc.

Inventors Nemunaitis, John J.; Rao, Donald; Brunicardi, F. Charles

Agent Pizzeys

Pub. Number AU-A-2010313441

PCT Pub. Number WO2011/053660

Priority 12/913,515 27.10.10 US; 61/256,867 30.10.09 US

Filing date 27 October 2010

Wipo publication date 5 May 2011

International Classifications

A61K 31/7105 (2006.01) - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links

A61K 48/00 (2006.01) Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases

A61P 35/00 (2006.01) Antineoplastic agents

C12N 15/113 (2010.01) Mutation or genetic engineering - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

C12N 15/63 (2006.01) Mutation or genetic engineering - Introduction of foreign genetic material using vectors

Event Publications

3 May 2012 PCT application entered the National Phase

  PCT publication WO2011/053660 Priority application(s): WO2011/053660

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010313447-Method of predicting risk of preterm birth

2010313438-Optical sensor assembly and method for measuring current in an electric power distribution system